In Deutschland erkranken nach Angaben des Robert-Koch-Instituts jährlich etwa 1.200 Menschen neu an einer chronischen myeloischen Leukämie (CML). Durch die Einführung von Tyrosinkinaseinhibitoren, die sich gegen das Fusionsprotein BCR-ABL1, eine pathologische Tyrosinkinase mit konstitutiver Aktivität richten, hat sich die Prognose der Betroffenen deutlich gebessert. Für einen Teil der Patienten bietet sich möglicherweise sogar die Chance auf eine andauernde therapiefreie Remission. Wie steht es um die Therapie von CML-Patienten in Deutschland?
This is a preview of subscription content, log in via an institution to check access.
Literatur
Engert A et al. The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica. 2016;101(2):115–208
Hoffmann VS et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015;29(6):1336–43
Hochhaus A et al. Chronisch Myeloische Leukämie (CML). Leitlinie. https://www.onkopedia.com/de/onkopedia/guidelines/chronische-myeloische-leukaemie-cml/@@view/html/index.html (abgerufen 28. Juli 2018)
Maynadie M et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica. 2013;98(2):230–8
Faderl S et al. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164–72
Mughal TI et al. Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms. Haematologica. 2014;99(5):797–801
Baccaran M et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6): 872–84
Pfirrmann M et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48–56
Cross NC et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015;29(5):999–1003
Hanfstein B et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia. 2014;28(10):1988–92
Hochhaus A et al. Befundinterpretation der molekularen Diagnostik in der Verlaufskontrolle der chronischen myeloischen Leukämie: Empfehlungen einer deutschen Expertengruppe. J Lab Med. 2012;36(6):405–11
Hughes TP et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116(19):3758–65
Hughes TP et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423–32
Hughes T et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28–37
Tesch H et al. Hohe molekulare Ansprechraten bei Patienten mit chronischer myeloischer Leukämie — eine retrospective Versorgungsstudie von mehr als 1.000 Patienten in Deutschland. DGHO. 2016;Abstr Poster 280
Weide R et al. Standard of Care of Patients with CML Treated in Community Based Oncology Group Practices in Rhineland-Palatinate (Germany). ASH.2016; Abstr Poster 2376. (Weide R et al. Standard of care of patients with Chronic Myeloid Leukemia (CML) treated in community based oncology group practices between 2001-2015 in Rhineland-Palatinate (Germany). Applied Cancer Res.2017;37:26
Hochhaus A et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31(7):1525–31
Kämpfe D et al. Treatment-free remissen up to 12 years. Interim analysis of a regional German CML register (a contribution of German CML-Alliance). EHA. 2018;Abstr PB1952
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Tesch, H., Jost, P., Dengler, J. et al. Therapieziel molekulare Remission in der Praxisroutine. Info Onkol. 21, 54–58 (2018). https://doi.org/10.1007/s15004-018-6335-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15004-018-6335-6